Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BarH like homeobox 1 (BARHL1)
- Target
- BARHL1
- Molecular classification
- Transcription factor, Homeobox protein
01
Overview
BarH like homeobox 1 (BARHL1) is a DNA-binding transcription factor from the homeobox family, critical for CNS development, sensory cell differentiation, and neural fate specification. The protein is highly expressed in neural precursors, the developing inner ear, and migration zones of the embryonic brain, supporting neuronal progenitor generation and the long-term maintenance of auditory hair cells vital for hearing and balance. Mutations or altered expression of BARHL1 are linked to neurodevelopmental disorders such as Joubert syndrome, and its expression is associated with cancer progression and neurodegenerative diseases. While a potential research and diagnostic target, it is not currently modulated by any approved drugs, and direct therapeutic targeting could entail CNS-specific safety challenges.
- Other names
- BarH1BARHL1BarH-like 1 homeobox protein
02
Mechanism of action
Not established for drugs, as there are currently no chemical modulators; research focuses on genetic and developmental mechanisms
03
Biological functions
Regulation of transcription (RNA polymerase II-specific)Sequence-specific double-stranded DNA bindingNeural development (e.g., cerebellum, diencephalon, spinal cord, midbrain)Sensory perception of sound (maintains auditory hair cells)
04
Disease associations
Cancer (including triple-receptor negative breast cancer)Alzheimer's diseaseHigh-grade gliomaJoubert syndrome (cerebellar development defect)Medulloblastoma, SHH-activated
05
Safety considerations
Therapeutic targeting could disrupt neural developmentLoss of BARHL1 expression causes auditory hair cell degenerationPotential for off-target effects in CNS and developmental processes
06
Interacting drugs
No approved drugs or defined chemical inhibitors are documented as directly interacting with BARHL1
07
Biomarkers
Expression levels in Alzheimer's disease and gliomaTriple-receptor negative breast cancer
Beyond the preview
Go deeper on BarH like homeobox 1 (BARHL1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BarH like homeobox 1 (BARHL1).